Loading clinical trials...
Loading clinical trials...
A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer
Conditions
Interventions
BKM120
Fulvestrant
+1 more
Locations
1
United States
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
November 14, 2011
Primary Completion Date
December 21, 2016
Completion Date
December 28, 2016
Last Updated
January 25, 2017
NCT06492759
NCT05422794
NCT06500455
NCT03723928
NCT04550494
NCT04704661
Lead Sponsor
Washington University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions